Dimethyl is a prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MedsAcross supplies Dimethyl for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: US FDA prescribing information
The mechanism by which dimethyl fumarate (DMF) exerts its therapeutic effect in multiple sclerosis is unknown. DMF and the metabolite, monomethyl fumarate (MMF), have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
Source: US FDA prescribing information
Starting dose: 120 mg twice a day, orally, for 7 days. Maintenance dose after 7 days: 240 mg twice a day, orally. Swallow TECFIDERA capsules whole and intact. Do not crush, chew, or sprinkle capsule contents on food. Take TECFIDERA with or without food
Source: US FDA prescribing information
TECFIDERA is contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of TECFIDERA. Reactions have included anaphylaxis and angioedema. Known hypersensitivity to dimethyl fumarate or any of the excipients of TECFIDERA.
Source: US FDA prescribing information
Anaphylaxis and Angioedema: Discontinue and do not restart TECFIDERA if these occur. Progressive Multifocal Leukoencephalopathy (PML): Withhold TECFIDERA at the first sign or symptom suggestive of PML. Herpes Zoster and Other Serious Opportunistic Infections: Consider withholding TECFIDERA in cases of serious infection until the infection has resolved. Lymphopenia: Obtain a CBC including lymphocyte count before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter. Consider interruption of TECFIDERA if lymphocyte counts <0.5 x 10 9 /L persist for more than six months. Liver Injury: Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating TECFIDERA and during treatment, as clinically indicated. Discontinue TECFIDERA if clinically significant liver injury induced by TECFIDERA is suspected.
Source: US FDA prescribing information
The following important adverse reactions are described elsewhere in labeling: Anaphylaxis and Angioedema. Progressive multifocal leukoencephalopathy. Herpes Zoster and Other Serious Opportunistic Infections. Lymphopenia. Liver Injury. Flushing. Serious Gastrointestinal Reactions Most common adverse reactions (incidence ≥10% and ≥2% placebo) were flushing, abdominal pain, diarrhea, and nausea.
Source: US FDA prescribing information
Store at 15°C to 30°C (59 to 86°F). Store in original container.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Dimethyl, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dimethyl 240 mg delayed-release capsuleOralGeneric name | — | US FDA | Available on request |
| Dimethyl 120 mg delayed-release capsuleOralGeneric name | — | US FDA | Available on request |
| Dimethyl 240 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Dimethyl 120 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Tecfidera kit | Biogen | US FDA | Available on request |
| Tecfidera 120 mg capsuleOral | Biogen | US FDA | Available on request |
| Tecfidera 240 mg capsuleOral | Biogen | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 7 presentations of Dimethyl and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Dimethyl, including Tecfidera.
Yes. The US FDA first approved Dimethyl on 27 March 2013, according to Drugs@FDA.
Yes. Dimethyl has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Dimethyl is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dimethyl is classified under ATC code L04AX07 (Dimethyl).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.